Challenges in β(3)-Adrenoceptor Agonist Drug Development
about
Role of Energy Metabolism in the Brown Fat Gene Program'Browning' the cardiac and peri-vascular adipose tissues to modulate cardiovascular riskAdipocyte ALK7 links nutrient overload to catecholamine resistance in obesityActivation of human brown adipose tissue by a β3-adrenergic receptor agonist.Activation of classical brown adipocytes in the adult human perirenal depot is highly correlated with PRDM16-EHMT1 complex expression.Glucagon increases energy expenditure independently of brown adipose tissue activation in humans.AHNAK deficiency promotes browning and lipolysis in mice via increased responsiveness to β-adrenergic signallingβ3 Adrenergic Stimulation Restores Nitric Oxide/Redox Balance and Enhances Endothelial Function in Hyperglycemia.Adrenergic regulation of cellular plasticity in brown, beige/brite and white adipose tissues.Distinct cellular and molecular mechanisms for β3 adrenergic receptor-induced beige adipocyte formation.Brown Adipose Tissue: an Update on Recent Findings.Novel Insights into How Overnutrition Disrupts the Hypothalamic Actions of Leptin.Evaluating the teratogenicity of the selective ß3-adrenoceptor agonist, CL 316.243 hydrate by employing FETAX (frog embryo teratogenesis assay).Rosiglitazone and a β3-Adrenoceptor Agonist Are Both Required for Functional Browning of White Adipocytes in Culture.Regulation of Human Adipose Tissue Activation, Gallbladder Size, and Bile Acid Metabolism by a β3-Adrenergic Receptor AgonistHDAC11 suppresses the thermogenic program of adipose tissue via BRD2Brown Adipose Tissue Energy Metabolism in Humans
P2860
Q26801658-81D3D3A0-7600-4CF8-9EA3-B4524ECA056AQ28066261-5CE54F1B-021F-4617-8549-08EA66326E51Q34069780-F62A4F3A-FAC7-460C-A578-E10B755A9F44Q34456901-54CE75E3-2A7A-49AD-A19A-7FBE07218F81Q35219668-C78091C4-0B29-47D7-91B5-8362BCE78BD6Q36457015-43BB5D8A-0808-4BE8-AAE1-8B070B58B107Q36700040-B35C7421-63F0-4907-A023-D357E771FBE9Q36714097-FC0FCFE2-CDBD-4B8E-B17C-FA4FEE8C4D7CQ37028404-BDB46FAD-B167-43F2-A687-240CEEABA520Q47135585-44339DB4-E61D-446E-8F02-CAAEB3B815C1Q47442499-7CA6517A-1437-414B-A0DA-C2EE61C67C78Q52597655-E7BC2121-5882-4729-9931-0F75DE465D2AQ53766567-154594D9-1B9A-4988-90F3-FE19CCCB9F5AQ55122222-BA09DF17-0B2B-4C5B-876A-02075B215728Q57106873-AAE60EF6-A44F-4F50-A520-2C82F5891A02Q58792327-458A825F-7EB4-428F-A9CC-3945CB794E40Q58797333-8B19C93A-62FE-4605-9F25-BD2197FD3FB5
P2860
Challenges in β(3)-Adrenoceptor Agonist Drug Development
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Challenges in β(3)-Adrenoceptor Agonist Drug Development
@ast
Challenges in β(3)-Adrenoceptor Agonist Drug Development
@en
type
label
Challenges in β(3)-Adrenoceptor Agonist Drug Development
@ast
Challenges in β(3)-Adrenoceptor Agonist Drug Development
@en
prefLabel
Challenges in β(3)-Adrenoceptor Agonist Drug Development
@ast
Challenges in β(3)-Adrenoceptor Agonist Drug Development
@en
P2860
P356
P1476
Challenges in β(3)-Adrenoceptor Agonist Drug Development
@en
P2093
Jonathan R S Arch
P2860
P356
10.1177/2042018811398517
P577
2011-04-01T00:00:00Z